-
41.
公开(公告)号:HU0600673A2
公开(公告)日:2006-12-28
申请号:HU0600673
申请日:2002-08-01
Applicant: SCHERING CORP
Inventor: ASBEROM THEODROS , GUZIK HENRY S , JOSIEN HUBERT B , PISSARNITSKI DMITRI A
IPC: C07D401/12 , A61K31/437 , A61K31/47 , A61K31/4709 , A61K31/496 , A61K31/5377 , A61P9/10 , A61P25/00 , A61P25/28 , A61P43/00 , C07D215/58 , C07D405/12 , C07D409/12 , C07D413/12 , C07D471/04 , C07D487/04 , C07D487/08 , C07D521/00
Abstract: This invention discloses novel gamma secretase inhibitors of the formula: wherein: R1 is a substituted aryl or substituted heteroaryl group; R2 is an R1 group, alkyl, -X(CO)Y, -(CR32)1-4X(CO)Y; each R3A is independently H or alkyl; X is -O-, -NH, or -N-alkyl; and Y is -NR6R7, or -N(R3)(CH2)2-6NR6R7. Also disclosed is a method of treating Alzheimer's Disease.
-
公开(公告)号:CA2261725C
公开(公告)日:2005-10-25
申请号:CA2261725
申请日:1997-08-06
Applicant: SCHERING CORP
Inventor: BARNETT ALLEN , SHERLOCK MARGARET , MCQUADE ROBERT , VICE SUSAN F , GREEN MICHAEL J , WANG YUGUANG , BERGER JOEL G , TOM WING , ASBEROM THEODROS , BROWNE MARGARET E , BOYLE CRAIG D , JOSIEN HUBERT B , DUGAR SUNDEEP , KOZLOWSKI JOSEPH A , CLADER JOHN W , MCCOMBIE STUART W , LOWE DEREK B , TAGAT JAYARAM R , CHEN LIAN-YONG , CHACKALAMANNIL SAMUEL , CHANG WEI K , VACCARO WAYNE D
IPC: C07D211/58 , A61K31/00 , A61K31/435 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/4523 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/495 , A61K31/496 , A61K31/50 , A61K31/501 , A61K45/00 , A61P25/28 , C07D211/24 , C07D211/32 , C07D211/96 , C07D239/34 , C07D257/04 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/145 , C07D295/15 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , A61K31/53
Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperidine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) wherein R, R1, R2, R3, R4, R21, R22, R28, X, Y and Z a s defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula with acetylcholinesterase inhibitors.
-
公开(公告)号:ZA200406237B
公开(公告)日:2005-09-22
申请号:ZA200406237
申请日:2004-08-04
Applicant: SCHERING CORP , PHARMACOPEIA DRUG DISCOVERY
Inventor: PISSARNITSKI DMITRI A , SMITH ELIZABETH M , ASBEROM THEODROS , HOBBS DOUGLAS W , JOSIEN HUBERT B , CLADER JOHN W , GUO TAO
IPC: C07D491/113 , A61K31/445 , A61K31/4535 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61P25/18 , A61P25/28 , A61P43/00 , C07D211/96 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/10 , C07D , A61K , A61P
Abstract: This invention discloses novel gamma secretase inhibitors of the formula: wherein: R 1 is a substituted aryl or substituted heteroaryl group; R 2 is an R 1 group, alkyl, -X(CO)Y, or alkylene-X(CO)Y wherein X and Y are as defined herein; each R 3 and each R 3A are independently H, or alkyl; R 11 is aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, or alkoxyalkyl. Also disclosed is a method of treating Alzheimer's Disease using one or more compounds of the invention.
-
公开(公告)号:ES2219919T3
公开(公告)日:2004-12-01
申请号:ES98958039
申请日:1998-11-23
Applicant: SCHERING CORP
Inventor: CHACKALAMANNIL SAMUEL , ASBEROM THEODROS , XIA YAN , DOLLER DARIO , CLASBY MARTIN C , CZARNIECKI MICHAEL F
IPC: C07D491/056 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4738 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P35/00 , A61P43/00 , C07D401/06 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D417/06 , C07D417/14 , C07D471/04 , C07D491/04 , C07D493/04 , C07D493/10
Abstract: Un compuesto representado por la fórmula estructural **(fórmula)** o una de sus sales farmacéuticamente aceptables, en donde: la línea punteada sencilla representa un enlace doble opcional; la línea punteada doble representa un enlace sencillo opcional; n es 0-2; Q es **(fórmula)** en donde n1 y n2 son independientemente 0-2; o cuando el enlace doble no está presente, Q también es heteroarilo Rsustituido o arilo R-sustituido condensado; R es 1 a 3 sustituyentes independientemente seleccionados del grupo que consiste en H, alquiloC, -C6, halógeno, hidroxi, amino, alquilo(C1-C6)amino, dialquil(C1-C6)amino, alcoxi(C1-C6), -COR16, -COOR17, -SOR16, -SO2R16NR16COR16a, -NR16COOR16a, -NR16CONR4R5, fluoro-alquilo(C1-C6), difluoro-alquilo(C1C6), trifluoro-alquilo (C1C6), cicloalquiloC3-C6, alqueniloC2-C6, aril-alquilo (C1-C6), aril-alquenilo(C2-C6), heteroaril-alquilo(C1-C6), heteroaril-alquenilo(C2-C6), hidroxi-alquilo(C1-C6), amino-alquilo (C1-C6), arilo y tio-alquilo(C1-C6); R1 y R2 se seleccionanindependientemente del grupo que consiste en H, alquiloC1-C6, fluoro-alquilo(C1-C6), difluoro-alquilo(C1-C6), trifluoro-alquilo(C1-C6), cicloalquiloC3-C6, alqueniloC2-C6, aril-alquilo(C1-C6), aril-alquenilo (C2-C6), heteroaril-alquilo(C1-C6), heteroaril-alquenilo(C2-C6), hidroxi-alquilo(C1-C6), amino-alquilo (C1-C6), arilo y tio-alquilo(C1-C6); o R1 y R2 juntos forman un grupo =O; R3 es H, hidroxi, alcoxiC1-C6, -SOR16, -SO2R17, -C(O)OR17, -C (O)NR16R19, alquiloC1-C6, halógeno, fluoro-alquilo (C1-C6), difluoro-alquilo(C1-C6), trifluoro-alquilo(C1-C6), cicloalquilo C3-C6, alqueniloC2-C6, aril-alquilo(C1-C6), arilalquenilo (C2-C6), heteroaril-alquilo(C1C5), heteroaril-alquenilo(C2-C6), hidroxi-alquilo(C1-C6), amino-alquilo(C1-C5), arilo o tio-alquilo (C1-C6); Het es un grupo heteroaromático mono-, bi- o tri-cíclico de 5 a 14 átomos comprendido de 1 a 13 átomos de carbono y 1 a 4 heteroátomos independientemente seleccionados del grupo que consiste en N, O y S, en donde un nitrógeno de anillo puede formar un N-óxido o un grupo cuaternario con un grupo alquiloC1-C4, en donde Het está unido a B por un miembro de anillo de átomo de carbono, y en donde el grupo Het está sustituido con 1 a 4 sustituyentes, W, independientemente seleccionados del grupo que consiste en H; alquiloC1-C6, fluoro-alquilo(C1-C6); difluoro-alquilo (C1C6); trifluoro-alquilo(C1-C6); cicloalquiloC3-C6; heterocicloalquilo; heterocicloalquilo sustituido con alquiloC1-C6.
-
公开(公告)号:BR0307492A
公开(公告)日:2004-11-23
申请号:BR0307492
申请日:2003-02-05
Applicant: SCHERING CORP , PHARMACOPEIA DRUG DISCOVERY
Inventor: PISSARNITSKI DMITRI A , JOSIEN HUBERT B , SMITH ELIZABETH M , CLADER JOHN W , ASBEROM THEODROS , GUO TAO , HOBBS DOUGLAS W
IPC: C07D491/113 , A61K31/445 , A61K31/4535 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61P25/18 , A61P25/28 , A61P43/00 , C07D211/96 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/10 , A61K31/4427
Abstract: This invention discloses novel gamma secretase inhibitors of the formula: wherein: R 1 is a substituted aryl or substituted heteroaryl group; R 2 is an R 1 group, alkyl, -X(CO)Y, or alkylene-X(CO)Y wherein X and Y are as defined herein; each R 3 and each R 3A are independently H, or alkyl; R 11 is aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, or alkoxyalkyl. Also disclosed is a method of treating Alzheimer's Disease using one or more compounds of the invention.
-
公开(公告)号:DK1036072T3
公开(公告)日:2004-09-06
申请号:DK98958039
申请日:1998-11-23
Applicant: SCHERING CORP
Inventor: CHACKALAMANNIL SAMUEL , ASBEROM THEODROS , XIA YAN , DOLLER DARIO , CZARNIECKI MICHAEL F , CLASBY MARTIN C
IPC: C07D491/056 , A61K31/4184 , A61K31/423 , A61K31/427 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4738 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K31/55 , A61P7/02 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P35/00 , A61P43/00 , C07D401/06 , C07D405/04 , C07D405/06 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/06 , C07D417/06 , C07D417/14 , C07D471/04 , C07D491/04 , C07D493/04 , C07D493/10
Abstract: Heterocyclic-substituted tricyclics of formula (I) or a pharmaceutically acceptable salt thereof, wherein: the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Q is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is -(CH2)n3-, wherein n3 is 0-5, -CH2-O-, -CH2S-, -CH2-NR -, -C(O)NR -. -NR C(O)-, (a), optionally substituted alkenyl or optionally substituted alkynyl; X is -O- or -NR - when the double dotted line represents a single bond, or X is -OH or -NHR when the bond is absent; Y is =O, =S, (H, H), (H, OH) or (H, C1-C6 alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y is =O, (H, H), (H, OH), (H, SH) or (H, C1-C6 alkoxy); R is absent when the double dotted line represents a single bond and is H, -NR R , or -OR when the bond is absent; or Y is (A) or (B) and R is H or C1-C6 alkyl; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.
-
公开(公告)号:AT258170T
公开(公告)日:2004-02-15
申请号:AT96906286
申请日:1996-02-16
Applicant: SCHERING CORP
Inventor: LOWE DEREK , CHANG WEI , KOZLOWSKI JOSEPH , BERGER JOEL G , MCQUADE ROBERT , BARNETT ALLEN , SCHERLOCK MARGARET , TOM WING , DUGAR SUNDEEP , CHEN LIAN-YONG , CLADER JOHN W , CHACKALAMANNIL SAMUEL , MCCOMBIE STUART W , TAGAT JAYARAM R , VICE SUSAN F , VACCARO WAYNE , WANG YUGUANG , GREEN MICHAEL J , BROWNE MARGARET E , ASBEROM THEODROS
IPC: C07D295/08 , A61K31/335 , A61K31/357 , A61K31/36 , A61K31/365 , A61K31/4427 , A61K31/443 , A61K31/445 , A61K31/4468 , A61K31/451 , A61K31/495 , A61K31/496 , A61K31/505 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61P25/28 , C07D211/14 , C07D211/22 , C07D211/24 , C07D211/26 , C07D211/32 , C07D211/58 , C07D211/62 , C07D239/34 , C07D257/04 , C07D271/06 , C07D295/02 , C07D295/03 , C07D295/084 , C07D295/088 , C07D295/096 , C07D295/112 , C07D295/116 , C07D295/12 , C07D295/125 , C07D295/13 , C07D295/135 , C07D295/14 , C07D295/145 , C07D295/15 , C07D307/33 , C07D309/12 , C07D317/28 , C07D317/62 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D405/14 , C07D409/14 , C07D401/10 , C07D403/10 , C07D407/04
Abstract: Di-N-substituted piperazine or 1,4 di-substituted piperadine compounds in accordance with formula I (including all isomers, salts, esters, and solvates) wherein R, R1, R2, R3, R4, R21, R27, R28, X, Y, and Z are as defined herein are muscarinic antagonists useful for treating cognitive disorders such as Alzheimer's disease. Pharmaceutical compositions and methods of preparation are also disclosed. Also disclosed are synergistic combinations of compounds of the above formula or other compounds capable of enhancing acetylcholine release with acetylcholinesterase inhibitors.
-
公开(公告)号:CA2478423A1
公开(公告)日:2003-08-14
申请号:CA2478423
申请日:2003-02-05
Applicant: SCHERING CORP , PHARMACOPEIA DRUG DISCOVERY
Inventor: SMITH ELIZABETH M , HOBBS DOUGLAS W , JOSIEN HUBERT B , GUO TAO , CLADER JOHN W , PISSARNITSKI DMITRI A , ASBEROM THEODROS
IPC: C07D491/113 , A61K31/445 , A61K31/4535 , A61K31/454 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/5377 , A61K31/541 , A61K31/55 , A61K31/551 , A61P25/18 , A61P25/28 , A61P43/00 , C07D211/96 , C07D401/04 , C07D401/12 , C07D401/14 , C07D405/14 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/14 , C07D471/10 , A61K31/4427
Abstract: This invention discloses novel gamma secretase inhibitors of the formula:(Chemical formula should be inserted here as it appears on abstract in paper form)wherein: R1 is a substituted aryl or substituted heteroaryl group ; R2 is an R1 group, alkyl, -X(CO)Y, or alkylene-X(CO)Y wherein X and Y are as defined herein; each R3 and each R3A are independently H, or alkyl; R11 is aryl, heteroaryl, alkyl, cycloalkyl, arylalkyl, arylcycloalkyl, heteroarylalkyl, heteroarylcycloalkyl, arylheterocycloalkyl, or alkoxyalkyl. Also disclosed is a method of treating Alzheimer s Disease using one or more compounds of the invention.
-
公开(公告)号:PE04152003A1
公开(公告)日:2003-05-22
申请号:PE0008212002
申请日:2002-08-27
Applicant: SCHERING CORP
Inventor: ASBEROM THEODROS , CHACKALAMANNIL SAMUEL , CLADER JOHN W , XU RUO , PISSARNITSKI DMITRI , STAMFORD ANDREW WILLIAM , WANG YUGUANG , HU YUEQING
IPC: A61K31/519 , A61K45/00 , A61P1/04 , A61P1/14 , A61P3/10 , A61P7/00 , A61P9/00 , A61P9/10 , A61P9/12 , A61P11/00 , A61P13/02 , A61P13/12 , A61P15/00 , A61P15/10 , A61P25/00 , A61P25/28 , A61P27/06 , A61P35/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D487/14 , C07D487/20
CPC classification number: C07D487/14
Abstract: SE REFIERE A COMPUESTOS DE FORMULAS I-1 Y II.1 DONDE q ES 0-1; R1 ES H, CICLOALQUILO, ALQUILO, R23-ALQUILO, R26; Ra, Rb, Rc SON H, ALQUILO, CICLOALQUILO, ARILO; Ra Y Rb FORMAN UN ANILLO DE 4 A 7 MIEMBROS, Rc ES H, ALQUILO; Ra Y Rb FORMAN UN ANILLO DE 4 A 7 MIEMBROS, Rb ES H, ALQUILO; i)X ES UN ENLACE; Y ES H, R26, CICLOALQUILO, ALQUILO, R25-ALQUILO, (CH2)tTCOR100, t ES 1-6; T ES O, NH; R100 ES H, R26-ALQUILO; R2 ES MONOHALOALQUILO, AZIDO, CIANO, OXIMINO, CICLOALQUENILO, HETEROARILO, R22-HETEROARILO, R27-ALQUILO; ii)X ES UNLACE; Y ES Q-V, Q ES UN ENLACE, ALQUILO C1-C8; V ES ARILO, R22-HETEROARILO, HETEROARILO; R2 ES H, HALO, CONHR6, CONR6R7, AZIDO, CIANO, C=N-OR6, CICLOALQUILO, ENTRE OTROS; iii)X ES O, S; R2 ES R26, CICLOALQUILO, CICLOALQUILALQUILO, HETEROCICLOALQUILO, ENTRE OTROS; iv)X ES O, S, R2 ES ALQUILO R26, CICLOALQUILO, CICLOALQUILALQUILO, ENTRE OTROS; SON COMPUESTOS PREFERIDOS 3-[(3-BROMO-4-HIDROXIFENIL)METIL]-5-ETIL-7,8-DIHIDRO-2-[(TETRAHIDRO-2H-PIRAN-4-IL)AMINO]-3H-IMIDAZO[2,1-b]PURIN-4-(5H)-ONA, 5'-ETIL-1'-[84-HIDROXIFENIL)METIL]-2'-(FENILETINIL)-ESPIRO[CICLOPENTANO-1,7'(8'H)-[1H]IMIDAZO[2,1-b]PURIN]-4'(5'H)-ONA; ENTRE OTROS; TAMBIEN SE REFIERE AL USO DEL COMPUESTO CON UN PROSTANOIDE, AGONISTA DEL RECEPTOR DE DOPAMINA, AGONISTA DE RECEPTOR MELANOCORTINA. LOS COMPUESTOS ELEVAN LOS NIVELES DE cGMP Y PUEDEN SER UTILES PARA EL TRATAMIENTO DE ENFERMEDAD UROGENITAL, VASCULAR PERIFERICA, ANGINA DE PECHO, RESTENOSIS DE POST ANGIOPLASTIA, DISFUNCION SEXUAL, IMPOTENCIA
-
公开(公告)号:DE69717109D1
公开(公告)日:2002-12-19
申请号:DE69717109
申请日:1997-07-08
Applicant: SCHERING CORP
Inventor: ASBEROM THEODROS , LOWE B , GREEN J
IPC: A61K31/00 , A61K31/443 , A61K31/4433 , A61K31/445 , A61K31/4465 , A61K31/4468 , A61K31/4545 , A61K45/06 , A61P25/28 , C07D211/58 , C07D405/12 , C07D405/14 , C07D409/14
Abstract: 1,4-Di-substituted piperidine muscarinic antagonists of formula (I) or a pharmaceutically acceptable salt, ester, or solvate thereof, wherein X is a bond, -O-, -S-, -SO-, -SO2-, -CO-, -C(OR )2-, -CH2-O-, -O-CH2-, -CH=CH-, -CH2-, -CH(C1-C6 alkyl)-, -C(C1-C6 alkyl)2-, -CONR -, -NR CO-, -SO2NR - or -NR SO2-; R is C3-C6 cycloalkyl, (a), (b), (c), (d), (e), optionally substituted phenyl or optionally substituted pyridyl; R is H, -CN, -CF3, alkyl, cycloalkyl, cycloalkenyl, alkenyl, -COR , -COO(alkyl, aryl, heteroaryl, alkylaryl or alkylheteroaryl), alkylaryl, alkylheteroaryl or -CON(R )2; R is cycloalkyl, cycloalkenyl, t-butoxycarbonyl or optionally substituted 4-piperidinyl; R and R are H, halo, -CF3, alkyl, alkoxy or -OH; R and R are H, alkyl, -CF3, alkoxy, -OH, alkylcarbonyl, alkoxycarbonyl, R CONH-, R OCONH-, R NHCONH- or NH2CONR -; R is H or alkyl, or the two R groups may form -(CH2)2-4; R is H, alkyl, cycloalkyl, -(alkyl)COOR , aryl, heteroaryl, alkylaryl, alkylheteroaryl and adamantyl; R is H or alkyl; R is H, C1-C20 alkyl, C1-C6 cycloalkyl, aryl or heteroaryl; and R is H, C1-C6 alkyl, aryl or heteroaryl; useful for treating cognitive disorders such as Alzheimer's disease are disclosed, as well as pharmaceutical compositions and methods of preparation. Also disclosed are combinations of compounds of formula (I) capable of enhancing ACh release with ACh'ase inhibitors.
-
-
-
-
-
-
-
-
-